ScoreComparison
Why is Fuji Pharma Co., Ltd. ?
1
Weak Long Term Fundamental Strength with a 11.50% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 9.85% and Operating profit at 11.50% over the last 5 years
3
Positive results in Mar 26
- NET SALES(HY) At JPY 29,716 MM has Grown at 23.33%
- NET PROFIT(HY) Higher at JPY 4,081.62 MM
- DEBT-EQUITY RATIO (HY) Lowest at 36.47 %
4
With ROCE of 9.18%, it has a expensive valuation with a 1.12 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 61.73%, its profits have risen by 38.3% ; the PEG ratio of the company is 0.3
5
Underperformed the market in the last 1 year
- The stock has generated a return of 61.73% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 85.83%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Fuji Pharma Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fuji Pharma Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Fuji Pharma Co., Ltd.
61.73%
1.22
36.48%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.85%
EBIT Growth (5y)
11.50%
EBIT to Interest (avg)
45.26
Debt to EBITDA (avg)
2.68
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.68
Tax Ratio
20.55%
Dividend Payout Ratio
34.57%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.78%
ROE (avg)
8.24%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.17
EV to EBIT
12.18
EV to EBITDA
7.58
EV to Capital Employed
1.12
EV to Sales
1.46
PEG Ratio
0.27
Dividend Yield
NA
ROCE (Latest)
9.18%
ROE (Latest)
11.59%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
NET SALES(HY)
At JPY 29,716 MM has Grown at 23.33%
NET PROFIT(HY)
Higher at JPY 4,081.62 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 36.47 %
DEBTORS TURNOVER RATIO(HY)
Highest at 3.31 times
DIVIDEND PER SHARE(HY)
Highest at JPY 3.31
-13What is not working for the Company
ROCE(HY)
Lowest at 5%
INTEREST(Q)
Highest at JPY 105 MM
Here's what is working for Fuji Pharma Co., Ltd.
Net Profit
At JPY 4,081.62 MM has Grown at 142.86%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Net Sales
At JPY 29,716 MM has Grown at 23.33%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Net Profit
Higher at JPY 4,081.62 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Debt-Equity Ratio
Lowest at 36.47 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 3.31 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Dividend per share
Highest at JPY 3.31
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Depreciation
Highest at JPY 1,052 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Fuji Pharma Co., Ltd.
Interest
At JPY 105 MM has Grown at 25%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Interest
Highest at JPY 105 MM
in the last five periods and Increased by 25% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
